healthy individuals
Conditions
Interventions
Ingestion of test food for 90 days
Sponsors
ROHTO Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Healthy female subjects aged between 25and 42 years at the time of informed consent (2) Subjects with a stable menstrual cycle (3) Subjects whose blood AMH is 0.5 ng/mL or more and less than 3.0 ng/mL (4) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing.
Exclusion criteria
Exclusion criteria: (1) Subjects with heart, liver, or kidney disease (including complications of other diseases) (2) Subjects with a history of cardiovascular disease (3) Subjects with diabetes (4) Subjects who suffer from diseases that may affect the results of the study, or who are undergoing treatment (5) Subjects with food and drug allergies (6) Subjects with symptoms of anemia that interfere with daily life (7) Female subjects who wish to become pregnant, who are pregnant (including those who may be pregnant), or who are breastfeeding while participating in this study (8) Subjects using female sex hormones, pyrroloquinoline quinone, coenzyme Q10 (9) Subjects who participate in strenuous sports and who are on a diet (10) Subjects with extremely irregular eating habits (11) Subjects who consume more than 60 g of pure alcohol per day (12) Subjects with a smoking habit (13) Subjects with a BMI of 30 or higher (14) Subjects participating in or planning to participate in other clinical trials at the start of this study (15) Subjects who are otherwise judged by the principal investigator or subinvestigator to be unsuitable for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood hormone levels | — |
Secondary
| Measure | Time frame |
|---|---|
| sex hormones oxidation marker MDQ | — |
Countries
Japan
Contacts
Public ContactMakoto Terashima
Oneness Support Co., Ltd. Clinical Trial Division
Outcome results
None listed